Effect of simvastatin on coronary heart disease patients with serum lipids and C reactive protein.docVIP

 PAGE \* MERGEFORMAT 7 Effect of simvastatin on coronary heart disease patients with serum lipids and C reactive protein [Keywords:] Coronary heart disease; simvastatin; lipid; C-reactive protein Coronary heart disease or coronary heart disease, refers to coronary atherosclerosis or a result of spasm associated with myocardial ischemia due to heart disease as the main feature. Clinical manifestations of angina, myocardial infarction, arrhythmia and other types of heart failure. With changing lifestyles, the disease has become a major cause of death among. statin lipid lowering drugs in addition to a role, there are anti-inflammatory effects, this study was to investigate the angina coronary heart disease with simvastatin on serum lipids and C reactive protein. 1 Materials and Methods 1.1 The study enrolled patients in this study were 64 patients are in line with WHO on the diagnostic criteria of ischemic heart disease. All the cases were in May 2003 -2009 in June I inpatient hospital patients, disease duration of 3 months to 12 years without and so on. including 39 males and 25 females, aged 43 to 78 years. 1.2 Research methods and treatment 64 patients were randomly divided into simvastatin group (n = 32) and the control group (n = 32 patients), two groups were smoking prohibition; have high blood pressure, controlling blood pressure. Simvastatin group the age of 44 to 78 (65.1 + -7.5) years, of which 19 males and 13 females, duration of 4 months to 12 years; the control group aged 43 to 77 (64.3 + -7.2) years, of which 20 males 12 females, disease duration of 3 months to 11 years. control group with isosorbide mononitrate (Xin Kang, North China Pharmaceutical Group Co., Ltd.) 40mg intravenous infusion, aspirin 100mg, before bedtime: the United States El Toro Seoul 12.5mg, 2 times / d, perindopril 4mg, 1 times / d, were treated for 4 weeks. the treatment group on the basis of oral simvastatin (lipid-lowering Shu, Hangzhou MSD Pharmaceutical Co.,